Profile
Amir Hasidim formerly worked at Beta-O2 Technologies Ltd., as Chief Executive Officer from 2021 to 2023, Quiet Therapeutics Ltd., as Director, Real-Time Radiography, Inc., as Chief Financial Officer, Tadiran Information Systems, as Principal, and JG Investments, as Principal.
Mr. Hasidim received his undergraduate degree and Masters Business Admin degree from The Hebrew University of Jerusalem.
Former positions of Amir Hasidim
| Companies | Position | End |
|---|---|---|
Beta-O2 Technologies Ltd.
Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Develops implantable bio-artificial pancreas devices | Chief Executive Officer | 01/01/2023 |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs | Director/Board Member | - |
Tadiran Information Systems | Corporate Officer/Principal | - |
JG Investments | Corporate Officer/Principal | - |
Real-Time Radiography, Inc.
Real-Time Radiography, Inc. Medical SpecialtiesHealth Technology Designs and manufactures flat-panel X-ray detectors | Director of Finance/CFO | - |
Training of Amir Hasidim
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 6 |
|---|---|
Real-Time Radiography, Inc.
Real-Time Radiography, Inc. Medical SpecialtiesHealth Technology Designs and manufactures flat-panel X-ray detectors | Health Technology |
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beta-O2 Technologies Ltd.
Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Develops implantable bio-artificial pancreas devices | Health Technology |
Tadiran Information Systems | |
JG Investments | |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs | Health Technology |
- Stock Market
- Insiders
- Amir Hasidim
















